CTOs on the Move

Neon Therapeutics

www.neontherapeutics.com

 
Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients. Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Neon Therapeutics raised $55M on 10/01/2015
Neon Therapeutics raised $36M on 12/05/2017

Similar Companies

Oragenics

Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CalciMedica

CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.